Medtronic upgraded to Buy, $100 target on $9.76B quarter
What's the deal? BTIGDealroom has a profile for this one. Try Dealroom → upgraded MedtronicDealroom has a profile for this one. Try Dealroom → to a Buy rating and raised its price target to $100, citing Q1 FY2027 revenue of $9.76 billion. The device maker's shares trade at $92.68, up 2.24%.
Why the upgrade? Revenue rose 13.7% to $9.8 billion, driven by demand across cardiovascular, neuroscience, and medical surgical segments. The company beat consensus estimates of $9.55 billion and raised its full-year organic revenue growth guidance.
What's the endgame? Medtronic is investing more than $700 million in Heart Tech and Robotics, signalling a focus on innovation and durable growth.
What else? The company offers a dividend yield above 3% and is nearing Dividend King status with 50 years of consecutive dividend increases, a draw for long-term investors.
The signal: Strong device demand and steady dividend growth are reinforcing Medtronic's position in healthcare technology, giving analysts confidence in its financial trajectory.
Read more: pluang.com
Image credit: usembassykyiv
